These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17360600)

  • 1. Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.
    Meltzer HY
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3019-20. PubMed ID: 17360600
    [No Abstract]   [Full Text] [Related]  

  • 2. Antipsychotic drugs and schizophrenia.
    Essock SM; Covell NH; Jackson CT
    N Engl J Med; 2006 Jan; 354(3):298-300; author reply 298-300. PubMed ID: 16422020
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new antipsychotic compounds: is a clinical choice algorithm possible?
    Wirshing WC
    West J Med; 1998 Jul; 169(1):43-4. PubMed ID: 9682633
    [No Abstract]   [Full Text] [Related]  

  • 5. Two new atypical antipsychotics: advantages and disadvantages.
    Lemon MD
    S D J Med; 1998 Aug; 51(8):285-6. PubMed ID: 9724957
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current pharmacotherapy of schizophrenia].
    Bitter I
    Orv Hetil; 2004 Jan; 145(3):105-9. PubMed ID: 15027331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?
    Meltzer HY
    Int J Neuropsychopharmacol; 2005 Jun; 8(2):153-6. PubMed ID: 15780147
    [No Abstract]   [Full Text] [Related]  

  • 9. The value of atypical antipsychotics in the treatment of schizophrenia.
    Jessen LM
    Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cataracts and quetiapine.
    Valibhai F; Phan NB; Still DJ; True J
    Am J Psychiatry; 2001 Jun; 158(6):966. PubMed ID: 11384916
    [No Abstract]   [Full Text] [Related]  

  • 12. The CATIE schizophrenia effectiveness trial.
    Delisi LE; Nasrallah HA
    Schizophr Res; 2005 Dec; 80(1):v-vi. PubMed ID: 16291292
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.
    Sahoo S; Ameen S; Akhtar S
    Aust N Z J Psychiatry; 2007 Jul; 41(7):629. PubMed ID: 17691161
    [No Abstract]   [Full Text] [Related]  

  • 14. New antipsychotic medications: more than old wine and new bottles.
    Schulz SC
    Bull Menninger Clin; 2000; 64(1):60-75. PubMed ID: 10695160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients.
    Suzuki Y; Watanabe J; Fukui N; Ozdemir V; Someya T
    BMJ; 2009 May; 338():a1792. PubMed ID: 19470561
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.
    Lin YH; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):613-5. PubMed ID: 16194268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
    Mosolov SN; Kabanov SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
    [No Abstract]   [Full Text] [Related]  

  • 19. Differing tolerability profiles among atypical antipsychotics.
    Hellewell JS; Haddad PM
    Am J Psychiatry; 2001 Mar; 158(3):501-2. PubMed ID: 11230007
    [No Abstract]   [Full Text] [Related]  

  • 20. Antipsychotic-associated weight gain.
    Gentile S
    Ann Pharmacother; 2004 May; 38(5):903-4. PubMed ID: 14996995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.